文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

前列腺癌、膀胱癌和肾癌患者的财务毒性:系统综述与行动呼吁

Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action.
PubMed 文献 · Eur Urol Oncol · 2021-04-02

研究建议未来纳入正式财务毒性框架和经过验证的工具。

要点

  • 财务毒性在前列腺癌和膀胱癌患者中常见,肾癌患者中尚未充分描述。
  • 财务毒性与较低生活质量和治疗/药物不依从相关。
  • 未来研究应使用经过验证的财务毒性工具并纳入患者报告结局。

核心结论

  • 尽管文献有限,财务毒性在前列腺癌和膀胱癌患者中常见,在肾癌患者中仍未被充分描述。

主要发现

  • 财务毒性的协变量、方法和测量存在显著异质性。
  • 与财务毒性相关的因素包括诊断时年轻、黑人种族、低社会经济地位、低教育程度和农村居住。
  • 财务毒性常与较低生活质量和治疗/药物不依从相关。
  • 财务毒性在实施全民健康覆盖的国家和未实施的国家均常见,但成本性质不同。

临床怎么用

  • 临床医生应关注前列腺癌、膀胱癌和肾癌患者的财务毒性,尤其是年轻、黑人种族、低社会经济地位、低教育程度和农村居住者。
  • 评估财务毒性有助于识别可能影响生活质量和治疗依从性的风险患者。

局限性

  • 文献数量有限,尤其肾癌研究仅2项。
  • 财务毒性的协变量、方法和测量存在显著异质性。
  • 肾癌患者的财务毒性特征尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Financial toxicity (FT) refers to the detrimental effects of financial strain caused by a cancer diagnosis on the well-being of patients and their families. It is highly prevalent among cancer patients and has been associated with inferior clinical outcomes. OBJECTIVE: To summarize the literature regarding FT among patients with prostate, bladder, and kidney cancer, and to propose a framework for future FT investigations. EVIDENCE ACQUISITION: Primary manuscripts and abstracts reporting FT as a primary or secondary outcome or a covariate in patients with prostate, bladder, or kidney cancer, published before May 2020, were retrieved using the PubMed, Scopus, Embase, CINAHL, and Cochrane databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Of 629 titles identified, 19, ten, and two studies met the inclusion criteria for prostate, bladder, and kidney cancer, respectively, and were included (24 unique articles). EVIDENCE SYNTHESIS: Significant heterogeneity was observed in covariates, methodology, and measure of FT. Factors commonly associated with FT included younger age at diagnosis, black race, low socioeconomic status, low education attainment, and rurality. FT was commonly associated with lower quality of life and nonadherence. FT was common among patients in countries with universal health coverage as well as those without, although the nature of these costs differed. CONCLUSIONS: Despite paucity of literature, it is suggested that FT is common among patients with prostate and bladder cancer, and remains uncharacterized in kidney cancer patients. Future work will benefit from the incorporation of a formal FT framework, utilization of validated FT instruments to characterize FT consistently, and inclusion of FT measures in outcomes reported by patients with genitourinary cancers. PATIENT SUMMARY: Financial toxicity affects many prostate, bladder, and kidney cancer patients; however, this toxicity is understudied. It is associated with decreased quality of life and lower medication and treatment adherence.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bhanvadia SK, Psutka SP, Burg ML, et al. Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. Eur Urol Oncol. 2021. PMID: 33820747. doi:10.1016/j.euo.2021.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。